Welcome to our dedicated page for Lobe Sciences news (Ticker: LOBEF), a resource for investors and traders seeking the latest updates and insights on Lobe Sciences stock.
Lobe Sciences Ltd. (OTCQB: LOBEF) generates news primarily as a clinical-stage biopharmaceutical company advancing therapies for diseases with significant unmet medical needs. The company’s disclosures highlight programs in rare neurological and hematological conditions, including chronic cluster headache and sickle cell disease, advanced through its subsidiaries Cynaptec Pharmaceuticals, Inc. and Altemia, Inc.
News updates for Lobe Sciences often cover developments in its lead CNS therapeutic candidate L-130 (also referred to as Conjugated Psilocin™ or psilocin mucate), which is being developed by majority-owned Cynaptec for chronic cluster headache and potential additional CNS indications under strategic review. Announcements have described completion of a Phase 1a study in healthy volunteers, ongoing work aligned with U.S. FDA Pre-IND guidance, and financing transactions at the subsidiary level intended to support further development.
Investors and followers of LOBEF can also expect coverage of Altemia, Inc.’s work on S-100, an early-stage therapeutic candidate for sickle cell disease, and a proprietary medical food in early-stage distribution aimed at addressing nutritional deficiencies commonly observed in patients with sickle cell disease. Company news has discussed how Lobe prioritizes S-100 within its sickle cell program and maintains limited commercialization efforts while assessing reimbursement pathways.
Lobe Sciences’ news flow additionally includes corporate and capital markets updates, such as private placements, debt settlements through equity issuance, leadership transition, Board renewal, and the appointment of new directors with experience in corporate governance, securities law, and international pharmaceutical business development. The company also reports on participation in industry conferences and patient-focused events related to cluster headache and other underserved conditions. Readers interested in LOBEF can use this news page to follow the company’s clinical progress, financing activities, governance developments, and strategic initiatives as disclosed in its official releases.
Lobe Sciences (OTCQB:LOBEF) announced that CEO Dr. Frederick D. Sancilio will be in Miami, Florida during the Jefferies and Leerink Healthcare Conferences on March 2026 and is available for investor and partner meetings.
The company advances preclinical and early-stage therapeutic assets via focused subsidiaries and is currently progressing two patented programs: L-130 for chronic cluster headache and S-100 for sickle cell disease, with additional programs under evaluation in substance use disorder and other neurological indications.
Lobe Sciences (OTCQB:LOBEF) reported Q1 fiscal 2026 results for the quarter ended November 30, 2025, highlighting increased R&D activity and maintained liquidity. Cash was $5.99M, short-term investments $1.03M, and net working capital $4.05M. R&D rose to $982,087 as L-130 preclinical and regulatory work advanced; net loss was $1.31M. The company reiterated progress via its 64% subsidiary Cynaptec (L-130) and early-stage S-100 program, while noting commercialization and reimbursement uncertainty for a medical food effort in Georgia.
Lobe Sciences (OTCQB:LOBEF) appointed Mr. Nick Karakochuk to its Board of Directors effective January 13, 2026, to bolster governance and capital markets expertise as the company builds on fiscal 2025 momentum.
Mr. Karakochuk is a corporate and securities lawyer focused on mergers and acquisitions, public and private financings, corporate reorganizations, and exchange and securities compliance. In connection with his appointment he was granted 3,500,000 restricted share units under the company's equity incentive plan.
Lobe Sciences (OTCQB:LOBEF) reported audited FY2025 results and an operational update following a leadership transition. Key balance-sheet improvements include cash of $5,854,118, a working capital surplus of $5,163,526, and short-term investments of $1,686,688 as of August 31, 2025. The current portion of convertible notes was eliminated and derivative liability fell to $205,105. FY2025 net loss attributable to the parent was $4,861,611 (loss per share $0.03). The company moved its L-130 program into subsidiary Cynaptec and completed a subsidiary financing that raised $8.46 million at a $22.56 million post-money valuation while retaining 64% ownership. Management says the changes reduce liquidity risk and focus development on two core programs for FY2026.
Lobe Sciences (OTCQB:LOBEF) reported audited FY2025 results and outlined a strategic transformation after a late‑2024 leadership and board change. The company strengthened liquidity: cash $5,854,118, short‑term investments $1,686,688, and working capital $5,163,526 as of August 31, 2025. FY2025 net loss attributable to parent was $4,861,611 (loss per share $0.03). Management moved its lead program L‑130 into subsidiary Cynaptec, which completed a $8,460,000 financing at a $22,560,000 post‑money valuation, leaving Lobe with a 64% stake. Company emphasized reduced legacy liabilities, improved governance, and focus on L‑130 (cluster headache) and S‑100 (sickle cell disease) while noting commercialization and reimbursement risks for a proprietary medical food.
Lobe Sciences (OTCQB:LOBEF) closed a related‑party debt settlement on October 23, 2025, issuing 3,837,686 common shares at C$0.05 per share to settle USD 137,130 (CAD 191,884.32) owed to Clearway Global, LLC.
The settlement is intended to strengthen the balance sheet and preserve cash for growth. The Settlement Shares carry a statutory four‑month hold period under Canadian securities laws. The creditor is a related party (holds >20% and is owned/controlled by a director/officer) and the directors relied on exemptions under MI 61‑101 for valuation and minority approval.
Lobe Sciences (OTCQB:LOBEF) announced a proposed related‑party debt settlement on October 9, 2025 converting USD 137,130 (CAD 191,884.32) of accounts payable into 3,837,686 common shares at C$0.05 per share. The Settlement Shares will carry a statutory four‑month hold period and closing is subject to Canadian Securities Exchange approval. The creditor, Clearway Global, is a related party holding >20% and owned by a director/officer; the company relied on MI 61‑101 exemptions for valuation and minority approval. Management said the conversion strengthens the balance sheet and preserves cash for growth.
Lobe Sciences Ltd. (OTCQB: LOBEF), a clinical stage biopharmaceutical company, will participate in the upcoming ArcStone-Kingswood Growth Summit on September 18, 2025 at the St. Regis Toronto. CEO Dr. Frederick D Sancilio will present the company's recent milestones and growth strategy.
The summit will feature over 20 companies and includes pre-arranged 1-on-1 meetings with investors, panel discussions, and networking opportunities. The event provides a platform for investors to connect with industry professionals and stay updated on key developments.
Lobe Sciences (OTCQB:LOBEF) announced its participation in the Clusterbusters 20th Annual U.S. Patient Conference from September 11-14, 2025, in Grapevine, Texas. The company will present research on its lead compound, L-130, Conjugated Psilocin™, being developed for chronic cluster headache treatment.
The company recently secured $6 million in funding for its subsidiary Cynaptec Pharmaceuticals, with an investor option for up to $20 million to complete FDA submission of L-130. Lobe aims to engage with patients at the conference to establish a patient advocacy team and design meaningful clinical endpoints.
Lobe Sciences (OTCQB:LOBEF), a clinical stage biopharmaceutical company, has appointed Marco Mastrodonato to its Board of Directors. Mastrodonato brings significant pharmaceutical and biotechnology industry experience, having previously co-founded Sinclair Pharma plc and served as Executive Director of the London Stock Exchange-listed company.
Mastrodonato's extensive background includes founding Metrodora Therapeutics and serving as CEO of BMG Pharma, where he leads development of hyaluronic acid-based technologies. Dr. Fred Sancilio, Lobe Sciences' Chairman and CEO, highlighted their 30-year professional relationship and Mastrodonato's proven success across European and Middle Eastern markets.